Neuphoria Therapeutics's market cap is currently $7.15M. The company's EPS TTM is $-0.005; its P/E ratio is ―; Neuphoria Therapeutics is scheduled to report earnings on February 20, 2025, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 24	Jun 22	Jun 21	Jun 20
Income Statement
Total Revenue	AU$ 0.00	AU$ 260.00K	AU$ 0.00	AU$ 50.00K
Gross Profit	AU$ -434.45K	AU$ -6.87M	AU$ -3.62M	AU$ -1.96M
Operating Income	AU$ -17.89B	AU$ -21.34M	AU$ -11.92M	AU$ -9.01M
EBITDA	AU$ -9.84M	AU$ -11.51M	AU$ -4.97M	AU$ -4.19M
Net Income	AU$ -15.49B	AU$ -21.76M	AU$ -8.70M	AU$ -7.12M
Balance Sheet
Cash & Short-Term Investments	AU$ 12.61M	AU$ 23.17M	AU$ 21.37M	AU$ 3.16M
Total Assets	AU$ 27.65M	AU$ 45.09M	AU$ 40.69M	AU$ 23.78M
Total Debt	AU$ 272.74K	AU$ 476.97K	AU$ 651.53K	AU$ 8.43M
Net Debt	AU$ -12.37M	AU$ -22.70M	AU$ -20.72M	AU$ 5.27M
Total Liabilities	AU$ 10.16M	AU$ 5.80M	AU$ 5.00M	AU$ 15.03M
Stockholders' Equity	AU$ 11.68M	AU$ 39.29M	AU$ 35.69M	AU$ 8.75M
Cash Flow
Free Cash Flow	AU$ -14.68M	-	-	-
Operating Cash Flow	AU$ -14.68M	AU$ -15.02M	AU$ -5.65M	AU$ -2.69M
Investing Cash Flow	AU$ 0.00	AU$ 429.23K	-	AU$ -134.66K
Financing Cash Flow	AU$ 15.11M	AU$ 18.64M	AU$ 23.66M	AU$ -3.70M

Currency in AUD

Neuphoria Therapeutics Earnings and Revenue History

Income Statement >

Neuphoria Therapeutics Debt to Assets

Balance Sheet >

Neuphoria Therapeutics Cash Flow

Cash Flow >

Neuphoria Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing